Tibolone

Tibolone has estrogenic effects on bone and reduces the risk of fracture in postmenopausal women to a similar extent to estrogen therapy. It is typically used for women younger than 60 years who have menopausal symptoms.

The safety profile of tibolone is less extensively studied than that of estrogen, but it appears to increase the recurrence of breast cancer in patients previously treated for breast cancer. It may increase the risk of stroke, particularly in women older than 60 years.

If tibolone is suitable, use:

Tibolone has progestogenic effects, so does not need to be given with progestogen therapy.